| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | 0 | 15.563 | 23.313 | 0 | 0 | 0 | - | - | - |
| Total Income - EUR | 0 | 0 | 15.793 | 23.313 | 0 | 0 | 0 | - | - | - |
| Total Expenses - EUR | 0 | 0 | 9.525 | 40.205 | 14.965 | 22.637 | 5.875 | - | - | - |
| Gross Profit/Loss - EUR | 0 | 0 | 6.269 | -16.893 | -14.965 | -22.637 | -5.875 | - | - | - |
| Net Profit/Loss - EUR | 0 | 0 | 6.111 | -17.186 | -14.965 | -22.637 | -5.875 | - | - | - |
| Employees | 0 | 0 | 1 | 1 | 0 | 0 | 0 | - | - | - |
Check the financial reports for the company - Oxygen Pharmaceutix Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 109 | 108 | 2.284 | 2.242 | 0 | 0 | 0 | - | - | - |
| Current Assets | 48 | 48 | 29.785 | 30.092 | 1.386 | 1.877 | 47 | - | - | - |
| Inventories | 0 | 0 | 28.038 | 24.869 | 0 | 0 | 0 | - | - | - |
| Receivables | 0 | 0 | 483 | 2.010 | 0 | 0 | 0 | - | - | - |
| Cash | 48 | 48 | 1.264 | 3.213 | 1.386 | 1.877 | 47 | - | - | - |
| Shareholders Funds | 45 | 45 | 6.155 | -11.144 | -25.893 | -48.038 | -52.848 | - | - | - |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | - | - | - |
| Debts | 112 | 111 | 25.915 | 43.478 | 27.278 | 49.916 | 52.895 | - | - | - |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Oxygen Pharmaceutix Srl